June 2019 newsletter
Therapeutic protein degradation by design Hot targets in drug discovery are constantly changing, paradigm shifts are a bit rarer. Protein ...
Macrocyclization of pharmaceutical compounds plays an increasing role in drug discovery. Macrocycles can provide several advantages such as favorable drug-like properties, and increased selectivity and binding affinity. Dr Matthias Bauer, Computational Chemist at Cresset, presents a case study of designing macrocyclization strategies for reported BRD4 inhibitors with Spark, Cresset’s bioisostere replacement and scaffold hopping tool.
Martin Slater and Sylvie Sciammetta explore the revival of interest in covalent inhibitors. This has culminated in a growing list of diverse proteins that have been successfully targeted, that are outside the well-trodden protease area.
Computational, medicinal and synthetic chemists can register for hands-on software workshops, which will take place on June 22 in Cambridge, UK.
The scientific program will be held on June 21. Presenters from the following companies are confirmed: AbbVie Inc., USA; Cancer Therapeutics CRC, Australia; Novartis, Switzerland; Sun Yat-Sen University, China; UCB Biopharma SPRL, Belgium; University of Cambridge, UK; University of Edinburgh, UK.